Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMRIX vs KEMADRIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Centrally acting muscle relaxant; it is the R-enantiomer of baclofen. Agonist at GABA-B receptors in the spinal cord, leading to inhibition of monosynaptic and polysynaptic spinal reflexes, thereby reducing muscle spasticity.
Centrally acting anticholinergic agent that blocks muscarinic receptors in the basal ganglia, reducing cholinergic overactivity and restoring dopamine-acetylcholine balance.
Treatment of spasticity due to multiple sclerosis, spinal cord injury, or other spinal cord disorders
Adjunctive treatment of Parkinson's disease,Drug-induced extrapyramidal reactions (acute dystonic reactions, parkinsonism, akathisia)
15 mg orally once daily. May increase to 30 mg once daily if needed, after at least 1 week. Maximum 30 mg/day.
2.5 mg orally three times daily, increased gradually to 5 mg three to four times daily if necessary; maximum 15-20 mg daily.
Terminal elimination half-life approximately 32 hours (range 28–40 hours); clinically relevant for once-daily dosing in chronic muscle spasm
6-10 hours in adults (terminal elimination half-life); may be prolonged in elderly or renal impairment.
Hepatic via deamination; primarily metabolized by monoamine oxidase B (MAO-B) to inactive metabolites.
Primarily metabolized by hepatic microsomal enzymes; metabolites are excreted in urine.
Renal: approximately 40% as unchanged drug and metabolites; biliary/fecal: minimal; total clearance: 2.5 L/min
Primarily renal as unchanged drug and metabolites (approximately 50% unchanged); minor biliary/fecal elimination (<10%).
40–45% bound to serum proteins, primarily albumin
~90%, primarily to albumin and alpha-1-acid glycoprotein.
5–8 L/kg; suggests extensive tissue distribution, including skeletal muscle
4-8 L/kg; indicates extensive tissue distribution (high lipophilicity).
Oral: 85–95% (extended-release formulation)
Oral: ~80% with first-pass metabolism reducing systemic exposure.
No specific dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min).
GFR >50 m L/min: no adjustment. GFR 10-50 m L/min: administer every 6 hours. GFR <10 m L/min: avoid use or administer every 12 hours.
Contraindicated in Child-Pugh class C. For Child-Pugh class A or B: initiate at 15 mg once daily; do not increase dose. Use with caution.
Contraindicated in severe hepatic impairment. In mild to moderate (Child-Pugh A or B): use with caution, reduce dose or extend dosing interval.
Safety and efficacy not established in pediatric patients under 12 years. For ages 12 and older, same as adult dosing.
Not established. Safety and efficacy in children under 12 years have not been determined.
Initiate at 15 mg once daily. Due to higher incidence of anticholinergic effects and falls, monitor closely; consider lower doses in frail elderly.
Initiate at low end of dosing range (2.5 mg once or twice daily); increase slowly. Monitor for confusion, urinary retention, constipation.
None
None.
Abrupt discontinuation may precipitate withdrawal syndrome including hallucinations, seizures, autonomic instability.,May cause sedation, dizziness, and muscle weakness; caution with activities requiring alertness.,Use with caution in patients with impaired renal function due to reduced clearance.,May exacerbate seizures in patients with epilepsy.,Avoid concomitant use with other CNS depressants.
May cause anticholinergic effects: confusion, hallucinations, urinary retention, constipation, blurred vision, heat stroke in hot weather,Use with caution in elderly patients due to CNS effects,Tardive dyskinesia: avoid abrupt withdrawal of antipsychotics when used for extrapyramidal symptoms,May exacerbate glaucoma, myasthenia gravis, gastrointestinal obstruction, and prostatic hypertrophy
Hypersensitivity to amrix or baclofen.,Abrupt withdrawal is contraindicated; must be tapered.,Concomitant use with MAO inhibitors is contraindicated due to risk of hypertensive crisis.
Known hypersensitivity to trihexyphenidyl,Narrow-angle glaucoma,Obstructive gastrointestinal disorders,Myasthenia gravis,Severe prostatic hypertrophy,Megaesophagus or esophageal achalasia
Avoid grapefruit and grapefruit juice during treatment as they may increase cyclobenzaprine levels. Taking AMRIX with or without food does not significantly affect absorption. Alcohol should be strictly avoided as it potentiates CNS depression.
No significant food interactions are known. However, taking with food may reduce gastrointestinal upset. Avoid excessive consumption of anticholinergic-containing foods or beverages (e.g., certain teas) as it may potentiate side effects.
Cyclobenzaprine (AMRIX) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, but adequate well-controlled studies in pregnant women are lacking. Use only if clearly needed. First trimester: no specific teratogenic effects documented; second and third trimesters: avoid near term due to potential neonatal effects (e.g., sedation, withdrawal).
Procyclidine (Kemadrin) is Pregnancy Category C. Animal studies are insufficient; no adequate human studies. First trimester: Avoid unless benefit outweighs risk; potential anticholinergic effects may cause fetal tachycardia. Second and third trimesters: Use with caution; neonatal anticholinergic effects (e.g., ileus, respiratory depression) reported near term.
Cyclobenzaprine is excreted into human milk in small amounts. M/P ratio: not established. Use with caution in nursing mothers; monitor infant for sedation, poor feeding, or hypotonia.
Excretion into breast milk is unknown; M/P ratio not established. Due to potential anticholinergic effects (e.g., drowsiness, gastrointestinal disturbances) in the infant, avoid use during breastfeeding or use with caution. Monitor infant for anticholinergic side effects.
No specific dose adjustments are recommended based on pharmacokinetic changes in pregnancy; however, due to potential for increased clearance, lowest effective dose should be used. Avoid use during labor and delivery due to potential neonatal depression.
No specific pharmacokinetic studies in pregnancy. Increased plasma volume and reduced gastrointestinal motility may alter absorption; however, no dose adjustment guidelines established. Use lowest effective dose. Monitor clinical response and adjust dosing based on anticholinergic side effects.
AMRIX (cyclobenzaprine extended-release) should not be used longer than 2-3 weeks due to lack of evidence for efficacy in muscle spasm beyond that period. It has significant anticholinergic effects; avoid in patients with glaucoma, urinary retention, or those taking MAOIs. Do not crush or chew capsules; administer once daily at same time. Onset of action is delayed compared to immediate-release cyclobenzaprine.
Kemadrin (procyclidine) is an anticholinergic agent used primarily for drug-induced parkinsonism and other extrapyramidal symptoms. Monitor for anticholinergic adverse effects, including dry mouth, blurred vision, urinary retention, and constipation. Use cautiously in elderly patients due to increased sensitivity. Avoid abrupt discontinuation to prevent withdrawal symptoms. May cause CNS effects such as dizziness or confusion.
Take AMRIX exactly once daily at the same time each day; do not crush, chew, or open the capsule.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they increase the risk of severe drowsiness and dizziness.,Do not drive or operate heavy machinery until you know how AMRIX affects you; it may cause drowsiness, dizziness, or blurred vision.,Contact your healthcare provider if you experience symptoms of serotonin syndrome (e.g., agitation, hallucinations, rapid heart rate, fever, muscle stiffness, nausea, diarrhea).,Do not use AMRIX for longer than 2-3 weeks unless specifically directed by your doctor; prolonged use is not recommended.,Inform your doctor if you have a history of urinary retention, glaucoma, thyroid disorders, heart problems, or liver disease.,If you miss a dose, take it as soon as you remember unless it is almost time for your next dose; do not double the dose.
Take exactly as prescribed; do not stop abruptly without consulting your doctor.,Avoid alcohol and other CNS depressants as they may increase drowsiness.,Report any vision changes, difficulty urinating, or severe constipation to your healthcare provider.,Use caution when driving or operating machinery until you know how this medication affects you.,Stay hydrated and use sugarless gum or hard candy to relieve dry mouth.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMRIX vs KEMADRIN, answered by our medical review team.
AMRIX is a Muscle Relaxant that works by Centrally acting muscle relaxant; it is the R-enantiomer of baclofen. Agonist at GABA-B receptors in the spinal cord, leading to inhibition of monosynaptic and polysynaptic spinal reflexes, thereby reducing muscle spasticity.. KEMADRIN is a Anticholinergic Antiparkinsonian that works by Centrally acting anticholinergic agent that blocks muscarinic receptors in the basal ganglia, reducing cholinergic overactivity and restoring dopamine-acetylcholine balance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMRIX and KEMADRIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMRIX is: 15 mg orally once daily. May increase to 30 mg once daily if needed, after at least 1 week. Maximum 30 mg/day.. The standard adult dose of KEMADRIN is: 2.5 mg orally three times daily, increased gradually to 5 mg three to four times daily if necessary; maximum 15-20 mg daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMRIX and KEMADRIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMRIX is classified as Category C. Cyclobenzaprine (AMRIX) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, but adequate well-controlled studies in pregnant women are lacki. KEMADRIN is classified as Category C. Procyclidine (Kemadrin) is Pregnancy Category C. Animal studies are insufficient; no adequate human studies. First trimester: Avoid unless benefit outweighs risk; potential anticho. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.